Skip to main content
https://pbs.twimg.com/media/F-yYbPsWcAAdUV7.jpg
ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO
Meral K. El Ramahi, MD
12-11-2023
×